#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Diffuse Large B‑ cell Lymphoma –  Modern Dia­gnostics and Molecularly Targeted Treatment


Authors: R. Pytlík;  M. Trněný
Authors place of work: I. interní klinika –  klinika hematologie 1. LF UK a VFN v Praze
Published in the journal: Klin Onkol 2015; 28(Supplementum 3): 64-72
doi: https://doi.org/10.14735/amko20153S64

Summary

Background:
Diffuse large B‑ cell lymphoma is a common label for a number of clinico‑ pathological entities, which differ in molecular pathogenesis, clinical presentation and prognosis. Exact correlation between clinico‑ pathological and molecular subtypes of diffuse large B‑ cell lymphoma was not optimally defined; however, key signal transduction pathways were identified; blockage of these pathways may be therapeutically significant.

Aim:
The purpose of this review is to show current approach to dia­gnostics of diffuse large B‑ cell lymphoma on molecular levels, to summarize current first‑line treatment options for newly diagnosed diffuse large B‑ cell lymphoma patients and to introduce new treatment possibilities, which are currently under investigation in clinical trials.

Results:
Current molecular dia­gnostics of diffuse large B‑ cell lymphoma is evolving in two main directions. One direction is classification according to gene expression or protein levels. According to these studies, patients may be divided into subgroups according to the cell of origin or according their stromal signature. Most frequently used is classification accord­ing cell of origin (COO), which divides diffuse large B-cell lymphomas into GCB subtype (germinal B-cell like) or ABC subtype (activated B-cell like). Second direction is studying genetic information on DNA level, where genetic mutations, deletions, amplifications and losses of heterozygozity are identified, which may be specific for subgroups defined by gene expression analysis, but may go across them. Both these directions aim at identifying signaling pathways important for survival and proliferation of tumor cells and in these, to identify targets for pharmacological block­age. Currently, standard of first-line treatment for all patients is antracycline‑based regimen with rituximab, which improved prognosis in both cell of origin subtypes, even if patients in the ABC subgroup have still inferior outcome. There is a number of new drugs with promising effectivity, which are studied in different phases of clinical trials (lenalidomide, bortezomib, idelalisib, venetoclax), but their possible effectivity will be limited only for precisely defined molecular subtypes of diffuse large B‑ cell lymphoma.

Conclusion:
The advent of new targeted drugs for diffuse large B‑ cell lymphoma is still awaited. For their effective use, besides the proof of their effectivity in randomized studies, also the extension of use of molecular methods in routine diagnostics and ensuring their wide availability will be necessary.

Key words:
diffuse large B‑ cell lymphoma –  gene expression profiling –  signal transduction pathways –  treatment

This study was supported by grants of Internal Grant Agency of the Czech Ministry of Health No. NT13072-4/2012 and NT12193-5/2011.

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Submitted:
25. 9. 2015

Accepted:
28. 9. 2015


Zdroje

1. Winter JN, Variakojis D, Epstein AL. Phenotypic analysis of established dif­fuse histiocytic lymphoma cel­l lines utiliz­ing monoclonal antibodies and cytochemical techniques. Blood 1984; 63(1): 140– 146.

2. Shawler DL, Wormsley SB, Dil­lman RO et al. The use of monoclonal antibodies and flow cytometry to detect peripheral blood and bone mar­row involvement of a dif­fuse, poorly dif­ferentiated lymphoma. Int J Im­munopharmacol 1985; 7(4): 423– 432.

3. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of dif­fuse large B‑ cel­l lymphoma identified by gene expres­sion profiling. Nature 2000; 403(6769): 503– 511.

4. Shipp MA, Ros­s KN, Tamayo P et al. Dif­fuse large B‑ cel­l lymphoma outcome prediction by gene‑ expres­sion profil­ing and supervised machine learning. Nat Med 2002; 8(1): 68– 74.

5. Monti S, Savage KJ, Kutok JL et al. Molecular profil­ing of dif­fuse large B‑ cel­l lymphoma identifies robust subtypes includ­ing one characterized by host inflam­matory response. Blood 2005; 105(5): 1851– 1861.

6. Tirado CA, Chen W, García R et al. Genomic profil­ing us­ing ar­ray comparative genomic hybridization define distinct subtypes of dif­fuse large B‑ cel­l lymphoma: a review of the literature. J Hematol Oncol 2012; 5: 54. doi: 10.1186/ 1756‑ 8722‑ 5‑ 54.

7. Nedomova R, Papajik T, Prochazka V et al. Cytogenetics and molecular cytogenetics in dif­fuse large B‑ cel­l lymphoma (DLBCL). Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2013; 157(3): 239– 247.

8. Jardin F. Next generation sequenc­ing and the management of dif­fuse large B‑ cel­l lymphoma: from whole exome analysis to targeted therapy. Discov Med 2014; 18(97): 51– 65.

9. Scott DW, Mottok A, En­nishi D et al. Prognostic significance of dif­fuse large B‑ cel­l lymphoma cel­l of origin determined by digital gene expres­sion in formalin‑fixed paraf­fin‑embedded tis­sue bio­psies. J Clin Oncol 2015; 33(26): 2848– 2856. doi: 10.1200/ JCO.2014.60.2383.

10. Armitage JO, Corder MP, Leimert JT et al. Advanced dif­fuse histiocytic lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) without maintenance therapy. Cancer Treat Rep 1980; 64(4– 5): 649– 654.

11. Coif­fier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with dif­fuse large‑ B‑ cel­l lymphoma. N Engl J Med 2002; 346(4): 235– 242.

12. Sehn LH, Donaldson J, Chhanabhai M et al. Introduction of combined CHOP plus rituximab therapy dramatical­ly improved outcome of dif­fuse large B‑ cel­l lymphoma in British Columbia. J Clin Oncol 2005; 23(22): 5027– 5033.

13. Pfreundschuh M, Trümper L, Osterborg A et al. CHOP‑like chemotherapy plus rituximab versus CHOP‑like chemotherapy alone in young patients with good‑ prognosis dif­fuse large‑ B‑ cel­l lymphoma: a randomized control­led trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7(5): 379– 391.

14. Nieman­n CU, Wiestner A. B‑ cel­l receptor signal­ing as a driver of lymphoma development and evolution. Semin Cancer Biol 2013; 23(6): 410– 421. doi: 10.1016/ j.semcancer.2013.09.001.

15. Majchrzak A, Witkowska M, Smolewski P. Inhibition of the PI3K/ Akt/ mTOR signal­ing pathway in dif­fuse large B‑ cel­l lymphoma: cur­rent knowledge and clinical significance. Molecules 2014; 19(9): 14304– 14315. doi: 10.3390/ molecules190914304.

16. Lenz G, Wright G, Dave S­s et al. Stromal gene signatures in large‑ B‑ cel­l lymphomas. N Engl J Med 2008; 359(22): 2313– 2323. doi: 10.1056/ NEJMoa0802885.

17. Pohlreich D, Vacková B, Pytlík R et al. Záchranná léčba a role transplantací u lymfomů. Klin Onkol 2015; 28 (Suppl 3):3S95–3S104. doi: 10.14735/ amko20153S95.

18. Stein H, Varnke RA, Chan WC et al. Dif­fuse large B‑ cel­l lymphoma, not otherwise specified. In: Swerdlow SH et al (eds). WHO Clas­sification of Tumours of Haematopoietic and Lymphoid Tis­sues. 4th ed. Lyon: International Agency for Research on Cancer 2008: 233– 237.

19. Rosenwald A, Wright G, Leroy K et al. Molecular dia­g­nosis of primary mediastinal B cel­l lymphoma identifies a clinical­ly favorable subgroup of dif­fuse large B cel­l lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198(6): 851– 862.

20. Dave S­S, Fu K, Wright GW et al. Molecular dia­gnosis of Burkitt‘s lymphoma. N Engl J Med 2006; 354(23): 2431– 2442.

21. Hum­mel M, Bentink S, Berger H et al. A bio­logic definition of Burkitt‘s lymphoma from transcriptional and genomic profiling. N Engl J Med 2006; 354(23): 2419– 2430.

22. Malumbres R, Chen J, Tibshirani R et al. Paraf­fin‑based 6- gene model predicts outcome in dif­fuse large B‑ cel­l lymphoma patients treated with R‑ CHOP. Blood 2008; 111(12): 5509– 5514. doi: 10.1182/ blood‑ 2008‑ 02‑ 136374.

23. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular clas­sification of dif­fuse large B‑ cel­l lymphoma by im­munohistochemistry us­ing a tis­sue microar­ray. Blood 2004; 103(1): 275– 282.

24. Coutinho R, Clear AJ, Owen A et al. Poor concordance among nine im­munohistochemistry clas­sifiers of cel­l‑ of‑ origin for dif­fuse large B‑ cel­l lymphoma: implications for therapeutic strategies. Clin Cancer Res 2013; 19(24): 6686– 6695. doi: 10.1158/ 1078‑ 0432.CCR‑ 13‑ 1482.

25. Gutiér­rez‑ García G, Cardesa‑ Salzman­n T, Climent F et al. Gene‑ expres­sion profil­ing and not im­muno­phenotypic algorithms predicts prognosis in patients with dif­fuse large B‑ cel­l lymphoma treated with im­munochemotherapy. Blood 2011; 117(18): 4836– 4843.

26. Benesova K, Forsterova K, Votavova H et al. The Hans algorithm failed to predict outcome in patients with dif­fuse large B‑ cel­l lymphoma treated with rituximab. Neoplasma 2013; 60(1): 68– 73. doi: 10.4149/ neo_2013_010.

27. Kulkarni M­M. Digital multiplexed gene expres­sion analysis us­ing the NanoStr­ing nCounter system. Cur­r Protoc Mol Biol 2011; chapter 25: unit25B.10. doi: 10.1002/ 0471142727.mb25b10s94.

28. Scott DW, Wright GW, Wil­liams PM et al. Determin­ing cel­l‑ of‑ origin subtypes of dif­fuse large B‑ cel­l lymphoma us­ing gene expres­sion in formalin‑fixed paraf­fin‑embedded tis­sue. Blood 2014; 123(8): 1214– 1217. doi: 10.1182/ blood‑ 2013‑ 11‑ 536433.

29. Scott DW, Mottok A, En­nishi D et al. Prognostic significance of dif­fuse large B‑ cel­l lymphoma cel­l of origin determined by digital gene expres­sion in formalin‑fixed paraf­fin‑embedded tis­sue bio­psies. J Clin Oncol 2015; 33(26): 2848– 2856. doi: 10.1200/ JCO.2014.60.2383.

30. Intlekofer AM, Younes A. Precision therapy for lymphoma –  cur­rent state and future directions. Nat Rev Clin Oncol 2014; 11(10): 585– 596. doi: 10.1038/ nrclinonc.2014.137.

31. Dunleavy K, Wilson WH. Appropriate management of molecular subtypes of dif­fuse large B‑ cel­l lymphoma.

Oncology (Wil­liston Park) 2014; 28(4): 326– 334.

32. Johnson NA, Slack GW, Savage KJ et al. Concur­rent expres­sion of MYC and BCL2 in dif­fuse large B‑ cel­l lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012; 30(28): 3452– 3459.

33. A predictive model for aggres­sive non‑Hodgkin‘s lymphoma. The International Non‑ Hodgkin‘s Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329(14): 987– 994.

34. Sehn LH, Ber­ry B, Chhanabhai M et al. The revised International Prognostic Index (R‑ IPI) is a better predictor of outcome than the standard IPI for patients with dif­fuse large B‑ cel­l lymphoma treated with R‑ CHOP. Blood 2007; 109(5): 1857– 1861.

35. Zhou Z, Sehn LH, Rademaker AW et al. An enhanced International Prognostic Index (NCCN‑ IPI) for patients with dif­fuse large B‑ cel­l lymphoma treated in the rituximab era. Blood 2014; 123(6): 837– 842. doi: 10.1182/ blood‑2013‑ 09‑ 524108.

36. Hamlin PA, Zelenetz AD, Kewalramani T et al. Age‑ adjusted International Prognostic Index predicts autologous stem cel­l transplantation outcome for patients with relapsed or primary refractory dif­fuse large B‑ cel­l lymphoma. Blood 2003; 102(6): 1989– 1996.

37. Advani RH, Chen H, Haberman­n TM et al. Comparison of conventional prognostic indices in patients older than 60 years with dif­fuse large B‑ cel­l lymphoma treated with R‑ CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E‑ IPI). Br J Haematol 2010; 151(2): 143– 151.

38. Procházka V, Pytlík R, Janíková A et al. A new prog­nostic score for elderly patients with dif­fuse large B‑ cel­l lymphoma treated with R‑ CHOP: the prognostic role of blood monocyte and lymphocyte counts is absent. PLoS One 2014; 9(7): e102594. doi: 10.1371/ journal.pone.0102594.

39. Pfreundschuh M, Trümper L, Kloes­s M et al. Two‑weekly or 3‑weekly CHOP chemotherapy with or with­out etoposide for the treatment of young patients with good‑ prognosis (normal LDH) aggres­sive lymphomas: results of the NHL‑B1 trial of the DSHNHL. Blood 2004; 104(3): 626– 633.

40. Pfreundschuh M, Trümper L, Kloes­s M et al.Two‑weekly or 3‑weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggres­sive lymphomas: results of the NHL‑B2 trial of the DSHNHL. Blood 2004; 104(3): 634– 641.

41. Cun­ningham D, Hawkes EA, Jack A et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly dia­gnosed dif­fuse large B‑ cel­l non‑Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14- day versus 21- day cycles. Lancet 2013; 381(9880): 1817– 1826. doi: 10.1016/ S0140‑ 6736(13)60313‑ X.

42. Delarue R, Til­ly H, Mounier N et al. Dose‑dense rituximab‑ CHOP compared with standard rituximab‑ CHOP in elderly patients with dif­fuse large B‑ cel­l lymphoma (the LNH03- 6B study): a randomised phase 3 trial. Lancet Oncol 2013; 14(6): 525– 533. doi: 10.1016/ S1470‑ 2045(13)70122‑ 0.

43. Pfreundschuh M, Nicken­ing C, Kan­nourakis G et al. Rituximab as a „chemo‑ equalizer“ in the MInT (Mabthera International Trial Group) study: treatment results of CHOP‑ 21, CHOEP‑ 21, MACOP‑ B and PMitCEBO with and without rituximab in young good‑ prognosis patients with aggres­sive lymphomas. An­n Oncol 2005; 16 (Suppl 5): v98.

44. Vitolo U, Chiapel­la A, Brusamolino E et al. Randomized multicentre phase III study for first line treatment of young patients with high risk (aaIPI 2– 3) dif­fuse large B‑ cel­l lymphoma (DLBCL): Rituximab (R) plus dose‑dense chemotherapy CHOP14/ MegaCHOP14 with or without intensified high‑dose chemotherapy (HDC) and autologous stem cel­l transplantation (ASCT). Results of DLCL04 trial of Italian Lymphoma Foundation (FIL) [abstract]. An­n Oncol 2011; 22 (Suppl 4): iv106.

45. Schmitz N, Nickelsen M, Ziepert M et al. Conventional chemotherapy (CHOEP‑ 14) with rituximab or high‑dose chemotherapy (MegaCHOEP) with rituximab for young, high‑risk patients with aggres­sive B‑ cel­l lymphoma: an open‑ label, randomised, phase 3 trial (DSHNHL 2002- 1). Lancet Oncol 2012; 13(12): 1250– 1259. doi: 10.1016/ S1470‑ 2045(12)70481‑ 3.

46. Cortelazzo S, Tarel­la C, Gian­ni AM et al. Chemoim­munotherapy with R‑ CHOP or high dose sequential ther­apy (R‑ HDS) with autologous stem cel­l transplantation (ASCT) for high risk DLBCL patients: preliminary results of the randomized RHDS0305 trial by Gruppo Italiano Terapie Inovative nei Linfomi (GITIL) [abstract]. Hematol Oncol 2013; 31 (Suppl 1): 136.

47. Stif­f PJ, Unger JM, Cook R et al. Autologous transplan­tation as consolidation for aggres­sive non‑Hodgkin‘s lymphoma. N Engl J Med 2013; 369(18): 1681– 1690. doi: 10.1056/ NEJMoa1301077.

48. Wiernik PH, Los­sos IS, Tuscano JM et al. Lenalidomide monotherapy in relapsed or refractory aggres­sive non‑Hodgkin’s lymphoma. J Clin Oncol 2008; 26(30): 4952– 4957. doi: 10.1200/ JCO.2007.15.3429.

49. Witzig TE, Vose JM, Zinzani PL et al. An international phase II trial of single‑agent lenalidomide for relapsed or refractory aggres­sive B‑ cel­l non‑Hodgkin’s lymphoma. An­n Oncol 2011; 22(7): 1622– 1627. doi: 10.1093/ an­nonc/ mdq626.

50. Lopez‑ Girona A, Mendy D, Ito T et al. Cereblon is a direct protein target for im­munomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012; 26(11): 2326– 2335. doi: 10.1038/ leu.2012.119.

51. Zhang LH, Kosek J, Wang M et al. Lenalidomide ef­ficacy in activated B‑ cel­l‑like subtype dif­fuse large B‑ cel­l lymphoma is dependent upon IRF4 and cereblon expres­sion. Br J Haematol 2013; 160(4): 487– 502. doi: 10.1111/ bjh.12172.

52. Hernandez‑ Ilizalitur­ri FJ, Deeb G, Zinzani PL et al. Higher response to lenalidomide in relapsed/ refractory dif­fuse large B‑ cel­l lymphoma in nongerminal center B‑ cel­l‑like than in germinal center B‑ cel­l‑like phenotype. Cancer 2011; 117(22): 5058– 5066. doi: 10.1002/ cncr.26135.

53. Nowakowski GS, LaPlant B, Macon WR et al. Lenalidomide combined with R‑ CHOP overcomes negative prog­nostic impact of non‑germinal center B‑ cel­l phenotype in newly dia­gnosed dif­fuse large B‑ Cel­l lymphoma: a phase II study. J Clin Oncol 2015; 33(3): 251– 257. doi: 10.1200/ JCO.2014.55.5714.

54. Karin M, Yamamoto Y, Wang QM. The IKK NF‑ kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004; 3(1): 17– 26.

55. Qin JZ, Zif­fra J, Sten­nett L et al. Proteasome inhibitors trigger NOXA‑ mediated apoptosis in melanoma and myel­oma cel­ls. Cancer Res 2005; 65(14): 6282– 6293.

56. Landowski TH, Megli CJ, Nul­lmeyer KD et al. Mitochondrial‑ mediated disregulation of Ca2+ is a critical determinant of Velcade (PS‑ 341/ bortezomib) cytotoxicity in myeloma cel­l lines. Cancer Res 2005; 65(9): 3828– 3836.

57. Befani CD, Vlachostergios PJ, Hatzidaki E et al. Bortezomib repres­ses HIF‑ 1α protein expres­sion and nuclear accumulation by inhibit­ing both PI3K/ Akt/ TOR and MAPK pathways in prostate cancer cel­ls. J Mol Med (Berl) 2012; 90(1): 45– 54. doi: 10.1007/ s00109‑ 011‑ 0805‑ 8.

58. Pel­lom ST Jr, Dudimah DF, Thounaojam MC et al. Modulatory ef­fects of bortezomib on host im­mune cel­l functions. Im­munotherapy. In pres­s 2015.

59. Dunleavy K, Pittaluga S, Czuczman MS et al. Dif­ferential ef­ficacy of bortezomib plus chemotherapy

within molecular subtypes of dif­fuse large B‑ cel­l lymphoma. Blood 2009; 113(24): 6069– 6676. doi: 10.1182/ blood‑ 2009‑ 01‑ 199679.

60. Ruan J, Martin P, Furman R­r et al. Bortezomib plus CHOP‑ rituximab for previously untreated dif­fuse large B‑ cel­l lymphoma and mantle cel­l lymphoma. J Clin Oncol 2011; 29(6): 690– 697. doi: 10.1200/ JCO.2010.31.1142.

61. Vajpayee N, Thakral C, Gopaluni S et al. Activation of mam­malian target of rapamycin in dif­fuse large B‑ cel­l lymphoma: a clinicopathological study. Leuk Res 2012; 36(11): 1403– 1409. doi: 10.1016/ j.leukres.2012.07.016.

62. Balasubramanian S, Crowley R, Sirisawad M et al. The Bruton‘s tyrosine kinase (BTK) inhibitor PCI‑ 32765 inhibits growth of ABC DLBCL tumors in vivo and in vitro by prevent­ing activation of pro‑survival NF‑ κB pathways. Blood 2011; 118: abstr. 4969.

63. Wilson WH, Gerecitano JF, Goy A et al. The Bruton’s Tyrosine kinase (BTK) inhibitor, ibrutinib (PCI‑ 32765), has preferential activity in the ABC subtype of relapsed/ refractory de novo dif­fuse large B‑ cel­l lymphoma (DLBCL): interim results of a multicenter, open‑ label, phase 2 study. Blood 2012; 120: 686.

64. Younes A, Thieblemont C, Morschhauser F et al. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R‑ CHOP) for treatment‑ naive patients with CD20- positive B‑ cel­l non‑Hodgkin lymphoma: a non‑randomised, phase 1b study. Lancet Oncol 2014; 15(9): 1019– 1126. doi: 10.1016/ S1470‑ 2045(14)70311‑ 0.

65. Dasmahapatra G, Patel H, Dent P et al. The Bruton tyrosine kinase (BTK) inhibitor PCI‑ 32765 synergistical­ly increases proteasome inhibitor activity in dif­fuse large‑ B cel­l lymphoma (DLBCL) and mantle cel­l lymphoma (MCL) cel­ls sensitive or resistant to bortezomib. Br J Haematol 2013; 161(1): 43– 56. doi: 10.1111/ bjh.12206.

66. Dunleavy K, Wilson WH. Dif­ferential role of BCL2 in molecular subtypes of dif­fuse large B‑ cel­l lymphoma. Clin Cancer Res 2011; 17(24): 7505– 7507. doi: 10.1158/ 1078‑ 0432.CCR‑ 11‑ 2372.

67. Zivny J, Klener P Jr, Pytlik R et al. The role of apoptosis in cancer development and treatment: focus­ing on the development and treatment of hematologic malignancies. Cur­r Pharm Des 2010; 16(1): 11– 33.

68. Green TM, Young KH, Visco C et al. Im­muno-histochemical double‑hit score is a strong predictor of outcome in patients with dif­fuse large B‑ cel­l lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012; 30(28): 3460– 3467.

69. Hu S, Xu‑ Monette ZY, Tzankov A et al. MYC/ BCL2 protein coexpres­sion contributes to the inferior survival of activated B‑ cel­l subtype of dif­fuse large B‑ cel­l lymphoma and demonstrates high‑risk gene expres­sion signatures: a report from the International DLBCL Rituximab‑ CHOP Consortium Program. Blood 2013; 121(20): 4021– 4031. doi: 10.1182/ blood‑ 2012‑ 10‑ 460063.

70. Pro B, Leber B, Smith M et al. Phase II multicenter study of oblimersen sodium, a Bcl‑ 2 antisense oligonucleotide, in combination with rituximab in patients with recur­rent B‑ cel­l non‑Hodgkin lymphoma. Br J Haematol 2008; 143(3): 355– 360. doi: 10.1111/ j.1365‑ 2141.2008.07353.x.

71. O‘Brien S, Moore JO, Boyd TE et al. 5‑year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol 2009; 27(31): 5208– 5212. doi: 10.1200/ JCO.2009.22.5748.

72. Kipps TJ, Eradat H, Grosicki S et al. A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT‑ 263) with or without rituximab, in previously untreated B‑ cel­l chronic lymphocytic leukemia. Leuk Lymphoma. In pres­s 2015.

73. Johnson‑ Farley N, Veliz J, Bhagavathi S et al. ABT‑ 199, a BH3 mimetic that specifical­ly targets Bcl‑ 2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in „double hit“ lymphoma cel­ls. Leuk Lymphoma 2015; 56(7): 2146– 2152. doi: 10.3109/ 10428194.2014.981172.

74. de Vos S, Flowers CR, Wang D et al. The BCL‑ 2 inhibitor ABT‑ 199 (GDC‑ 0199) in combination with bendamustine and rituximab in patients with relapsed or refractory non‑Hodgin’s lymphoma. Blood 2014; 124(21): abstr. 1722.

Štítky
Paediatric clinical oncology Surgery Clinical oncology

Článok vyšiel v časopise

Clinical Oncology

Číslo Supplementum 3

2015 Číslo Supplementum 3
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#